Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot P49768: Variant p.Met146Val

Presenilin-1
Gene: PSEN1
Feedback?
Variant information Variant position: help 146 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LP/P [Disclaimer] The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change: help From Methionine (M) to Valine (V) at position 146 (M146V, p.Met146Val). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Similar physico-chemical property. Both residues are medium size and hydrophobic. The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help 1 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Variant description: help In AD3; loss of function as calcium-leak channel; results in calcium overload in the endoplasmic reticulum. Any additional useful information about the variant.
Other resources: help Links to websites of interest for the variant.


Sequence information Variant position: help 146 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 467 The length of the canonical sequence.
Location on the sequence: help GQRALHSILNAAIMISVIVV M TILLVVLYKYRCYKVIHAWL The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 1 – 298 Presenilin-1 NTF subunit
Transmembrane 133 – 153 Helical
Mutagenesis 131 – 131 H -> R. Severe decrease of protease activity with APP.
Mutagenesis 136 – 136 A -> G. Decreased protease activity with APP.
Mutagenesis 143 – 143 I -> V. Increased amyloid-beta 42/amyloid-beta 40 ratio in vitro.
Mutagenesis 150 – 150 L -> P. Nearly abolishes protease activity with APP.
Mutagenesis 165 – 165 W -> G. Decreased protease activity with APP. Increased amyloid-beta 42/amyloid-beta 40 ratio in vitro.
Helix 125 – 155



Literature citations
Presenilins form ER Ca2+ leak channels, a function disrupted by familial Alzheimer's disease-linked mutations.
Tu H.; Nelson O.; Bezprozvanny A.; Wang Z.; Lee S.F.; Hao Y.H.; Serneels L.; De Strooper B.; Yu G.; Bezprozvanny I.;
Cell 126:981-993(2006)
Cited for: FUNCTION; CHARACTERIZATION OF VARIANT AD3 VAL-146; The structure of the presenilin 1 (S182) gene and identification of six novel mutations in early onset AD families.
Clark R.F.; Hutton M.; Fuldner R.A.; Froelich S.; Karran E.; Talbot C.; Crook R.; Lendon C.L.; Prihar G.; He C.; Korenblat K.; Martinez A.; Wragg M.; Busfield F.; Behrens M.I.; Myers A.; Norton J.; Morris J.; Mehta N.; Pearson C.; Lincoln S.; Baker M.; Duff K.; Zehr C.; Perez-Tur J.; Houlden H.; Ruiz A.; Ossa J.; Lopera F.; Arcos M.; Madrigal L.; Collinge J.; Humphreys C.; Asworth T.; Sarner S.; Fox N.C.; Harvey R.; Kennedy A.; Roques P.K.; Cline R.T.; Phillips C.A.; Venter J.C.; Forsel L.; Axelman K.; Lilius L.; Johnston J.; Cowburn R.; Viitanen M.; Winblad B.; Kosik K.S.; Haltia M.; Poyhonen M.; Dickson D.; Mann D.; Neary D.; Snowden J.; Lantos P.; Lannfelt L.; Rossor M.N.; Roberts G.W.; Adams M.D.; Hardy J.; Goate A.M.;
Nat. Genet. 11:219-222(1995)
Cited for: VARIANTS AD3 VAL-139; VAL-146; TYR-163; SER-267; ALA-280 AND GLY-280; Screening for PS1 mutations in a referral-based series of AD cases: 21 novel mutations.
Rogaeva E.A.; Fafel K.C.; Song Y.Q.; Medeiros H.; Sato C.; Liang Y.; Richard E.; Rogaev E.I.; Frommelt P.; Sadovnick A.D.; Meschino W.; Rockwood K.; Boss M.A.; Mayeux R.; St George-Hyslop P.;
Neurology 57:621-625(2001)
Cited for: VARIANTS AD3 GLN-35; VAL-79; CYS-115; ASN-116; THR-143; ILE-146; LEU-146; VAL-146; TYR-156 DELINS PHE-THR-TYR; ARG-163; LEU-177; SER-177; PRO-178; ALA-206; SER-206; GLU-209; LEU-213; ARG-222; THR-231; LEU-233; PRO-235; PHE-261; ARG-274; ARG-352 INS; ILE-354; GLN-358; TYR-365; VAL-394; PHE-418; GLU-431; PHE-435 AND VAL-439; VARIANT GLY-318;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.